Latest News | Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals Announces Dismissal of ICN Appeal Scheduled For Court Next Week

Cranberry Township, Pennsylvania, June 4, 2004– Three Rivers Pharmaceuticals, LLC today announced that the appeal filed by Valeant Pharmaceuticals International, formally ICN Pharmaceuticals Inc., scheduled for oral arguments next week in Washington, D.C. has been dismissed. [more]

Three Rivers Pharmaceuticals announces FDA Approval of Ribasphere™ (Ribavirin capsules) 200mg for the Treatment of Chronic Hepatitis C

Cranberry Township, PA – April 7, 2004– Three Rivers Pharmaceuticals, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its Ribasphere™ (Ribavirin capsules) 200mg in combination with interferon alfa-2b for the treatment of Hepatitis C (“HCV”). [more]

Three Rivers Pharmaceuticals Announces Receipt of ‘Approvable’ Letter for RIBASPHERE™ (Ribavirin, USP) Capsules 200mg

Cranberry Township, PA

February 23, 2004Three Rivers Pharmaceuticals announced today that it received an “Approvable” letter from the U.S. Food and Drug Administration (FDA) for RIBASPHERE™ (Ribavirin, USP) Capsules 200mg. [more]

Three Rivers Pharmaceuticals Announces Victory on Summary Judgment Motion in case with ICN Pharmaceuticals

Cranberry Township, Pennsylvania, July 16, 2003 – Three Rivers Pharmaceuticals, LLC today announced that the United States District Court for the Central District of California granted its motion for Summary Judgment in the patent infringement case filed against it by ICN Pharmaceuticals. [more]

Three Rivers Pharmaceuticals Announces Settlement Reached with Schering Corporation Over Ribavirin Lawsuit

Cranberry Township, PennsylvaniaFebruary 7, 2003
Three Rivers Pharmaceuticals, LLC today announced that it had reached final settlement with Schering Corporation in the patent litigation case involving the drug ribavirin (Rebetol). [more]

DSM Pharmaceuticals, Inc. Announces New Manufacturing Contract with Three Rivers Pharmaceuticals

July 18, 2002DSM Pharmaceuticals, Inc. in Greenville, North Carolina has signed a manufacturing and supply agreement with Three Rivers Pharmaceuticals of Cranberry Township PA. [more]

PAR Pharamaceutical Announces Licensing of Ribavirin From Three Rivers Pharmaceuticals

ANDA Filing with Paragraph IV Certification May Offer Co-Exclusive Marketing RightsSpring Valley, New York, July 08, 2002 — Par Pharmaceutical, Inc., a subsidiary of Pharmaceutical Resources, Inc., (“PRI”) (NYSE:PRX), today announced that it has entered into an agreement with Three Rivers Pharmaceuticals to market and distribute ribavirin 200 mg capsules. Ribavirin, a synthetic nucleoside analogue with antiviral activity, is indicated for the treatment of hepatitis C, a chronic condition suffered by approximately 4 million Americans. Schering-Plough currently markets ribavirin under the brand name Rebetol®. Rebetol® achieved U.S. sales of approximately $300 million in 2001. [more]

Three Rivers Pharmaceuticals Seeks Permission for Generic Treatment for Hepatitis C

Pittsburgh – August 24
Three Rivers Pharmaceuticals, LLC, a Pittsburgh-based and privately-owned company, has filed an Abbreviated Drug Application (ANDA) with the U.S. Food & Drug Administration (FDA) for permission to market the antiviral prescription drug ribavirin.
[more]